The turnaround in business F gathered further momentum with a notable uptrend in
revenues, profitability and cash flow management, despite disruptions in the supply chain
and mounting inflationary pressures in the macro-environment.
Dear Shareholders,
The world has been gradually coming to terms with the new normal in the aftermath of a
gradual receding of the COVID-19 pandemic. India, like the rest of the world, continued to
face challenges even in FY22 and the impact of the pandemic, further compounded by
geo-political events, continues to be felt both on the economy and communities in general.
At RPG Life Sciences, the continued adoption of stringent COVID-19 protocols, robust
systems and processes and digital initiatives helped mitigate the impact to a fair degree.
The turnaround in business gathered further momentum with a notable uptrend in revenues,
profitability and cash flow management, despite disruptions in the supply chain and
mounting inflationary pressures in the macroenvironment.
During the year, the Company maintained a strong focus on business continuity to ensure
minimum disruptions in manufacturing activity and supply chains while looking to
continuously improve sales and other performance metrics. Safety and wellbeing of its
people and their families, dealers, customers and communities continued to remain a key
focus area for the Company.
The Company is well poised to build on the strong operational competencies developed
over the last few years. I am hopeful that the Company will continue to grow and create
new milestones in the years to come.
Harsh V. Goenka
Chairman.